ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR39

CKD Prevalence, Patterns of Treatment, and Outcomes in Patients with Cancer: A Population-Based Cohort Study

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology

Authors

  • Kitchlu, Abhijat, University Health Network, Toronto, Ontario, Canada
  • Luo, Bin, Institute for Clinical Evaluative Sciences, London, Ontario, Canada
  • Jeyakumar, Nivethika, Institute for Clinical Evaluative Sciences, London, Ontario, Canada
  • Garg, Amit X., London Health Sciences Centre, London, Ontario, Canada
  • Amir, Eitan, University Health Network, Toronto, Ontario, Canada
  • Kim, Joseph, University Health Network, Toronto, Ontario, Canada
  • Wald, Ron, St. Michael's Hospital, Toronto, Ontario, Canada
Background

Chronic kidney disease (CKD) may impede optimal cancer treatment and result in worse outcomes. There are limited data to assess receipt of systemic therapy, radiation therapy, and palliative care in patients with cancer and CKD.

Methods

We conducted a population-based cohort study of all patients (≥18 years old) with a new cancer diagnosis in Ontario, Canada (2007-2015). We categorized patients according to CKD status at cancer diagnosis [estimated glomerular filtration rate (eGFR) ≥60 (referent group), 45-59, 30-44, 15-29, <15 mL/min/1.73m2, dialysis and transplant recipients]. We used multivariable Fine and Gray proportional hazards models to assess overall survival, receipt of systemic therapy, radiation and palliative care (6-months prior to death) in the 5 most common solid cancers (bladder, breast, colon, prostate, lung) and kidney cancer.

Results

We identified 128,489 patients with a new cancer diagnosis, of whom 16% had pre-existing CKD (eGFR <60 mL/min/1.73m2). Patients with the 6 cancers of interest accounted for 73% (93,751). Kidney function at cancer diagnosis was associated with (progressively) worse overall survival in CKD stages 3a-5, dialysis, and transplant recipients (Figure a). Increasing CKD stage was associated with significantly reduced receipt of all treatment modalities [systemic therapy, radiation and palliative care (Figure b-d)]. Patients receiving dialysis had 2-fold increased mortality in bladder, breast and colon cancers, and 3-fold mortality in kidney cancers.

Conclusion

In patients with cancer, CKD is associated with reduced exposure to systemic, radiation and palliative treatments and worse overall survival. Strategies to improve cancer care in the CKD population are needed.

Figure - Adjusted HR by CKD Status